An expert panel on the adequacy of safety data and physiological roles of dietary bovine osteopontin in infancy.

Autor:	Fleming SA; Traverse Science, Inc., Mundelein, IL, United States., Reyes SM; Rev Bioscience, LLC, Boise, ID, United States., Donovan SM; Department of Food Science and Human Nutrition, University of Illinois Urbana-Champaign, Urbana, IL, United States., Hernell O; Department of Clinical Sciences and Pediatrics, Umeå University, Umeå, Sweden., Jiang R; Department of Nutrition, University of California, Davis, Davis, CA, United States., Lönnerdal B; Department of Nutrition, University of California, Davis, Davis, CA, United States., Neu J; Department of Pediatrics, Division of Neonatology, University of Florida, Gainesville, FL, United States., Steinman L; Departments of Pediatrics and of Neurology and Neurological Sciences, Interdepartmental Program in Immunology, Beckman Center for Molecular Medicine, Stanford University School of Medicine, Stanford, CA, United States., Sørensen ES; Department of Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark., West CE; Department of Clinical Sciences and Pediatrics, Umeå University, Umeå, Sweden., Kleinman R; Harvard Medical School, Boston, MA, United States.; Department of Pediatrics, Massachusetts General Hospital, Boston, MA, United States., Wallingford JC; Nutrispectives, LLC, Spokane, WA, United States.
Jazyk:	angličtina
Zdroj:	Frontiers in nutrition [Front Nutr] 2024 Jun 11; Vol. 11, pp. 1404303. Date of Electronic Publication: 2024 Jun 11 (Print Publication: 2024).
DOI:	10.3389/fnut.2024.1404303
Abstrakt:	Human milk, due to its unique composition, is the optimal standard for infant nutrition. Osteopontin (OPN) is abundant in human milk but not bovine milk. The addition of bovine milk osteopontin (bmOPN) to formula may replicate OPN's concentration and function in human milk. To address safety concerns, we convened an expert panel to assess the adequacy of safety data and physiological roles of dietary bmOPN in infancy. The exposure of breastfed infants to human milk OPN (hmOPN) has been well-characterized and decreases markedly over the first 6 months of lactation. Dietary bmOPN is resistant to gastric and intestinal digestion, absorbed and cleared from circulation within 8-24 h, and represents a small portion (<5%) of total plasma OPN. Label studies on hmOPN suggest that after 3 h, intact or digested OPN is absorbed into carcass (62%), small intestine (23%), stomach (5%), and small intestinal perfusate (4%), with <2% each found in the cecum, liver, brain, heart, and spleen. Although the results are heterogenous with respect to bmOPN's physiologic impact, no adverse impacts have been reported across growth, gastrointestinal, immune, or brain-related outcomes. Recombinant bovine and human forms demonstrate similar absorption in plasma as bmOPN, as well as effects on cognition and immunity. The panel recommended prioritization of trials measuring a comprehensive set of clinically relevant outcomes on immunity and cognition to confirm the safety of bmOPN over that of further research on its absorption, distribution, metabolism, and excretion. This review offers expert consensus on the adequacy of data available to assess the safety of bmOPN for use in infant formula, aiding evidence-based decisions on the formulation of infant formula. Competing Interests: Support for the reported work are as follows: SF serves a consultant for Arla Foods Ingredients (AFI) and has received financial support to write the manuscript. SR serves as a consultant for Traverse Science and has received financial support to help write the manuscript. OH, RJ, BL, CW, ES, and SD have published research supported by AFI. SD, RJ, ES, and JW serve as consultants to AFI. All authors were compensated by AFI for their efforts to attend the workshop and draft, revise, or edit the manuscript. ES is an inventor of multiple patents related to the subject matter (US20210169117A1, US20070232526A1, US20090202449A1, US20030149249A1). Other disclosures in the past 36 months related to the subject matter but not directly to this manuscript are as follows. BL: Grants or contracts-Ausnutria, ByHeart, Hipp, Mead Johnson China, Mead Johnson Nutrition, Turtle Tree; Consulting, honoraria, or speaking-Mead Johnson Nutrition, Synlait; Advisory boards-Biostime, ByHeart, Dairy Goat Cooperative (New Zealand), Hero, Turtle Tree. JN: Grants or contracts-Infant Bacterial Therapeutics; Consulting, honoraria, or speaking-Infant Bacterial Therapeutics, Glycome, Medela, Nestle Nutrition Institute, Siolta Therapeutics; Advisory boards-Astarte, Medela, Nestle Nutrition Institute. JW: Other-Ownership of Nutrispectives. OH: Grants or contracts-Hero AB, Semper AB; Advisory-Dairy Goat Co-operative, Semper AB. SF: Grants or contracts-Abbott, Mead Johnson Nutrition, Nestle Nutrition, Prolacta Bioscience, Reckitt Benckiser; Other-Ownership of Traverse Science. SD: Grants or contracts-ByHeart, General Mills, IFF, Kyowa Hakka Bio, National Dairy Council, Nestle; Consulting, honoraria, or speaking-Ausnutria, Biostime, DSM, Nestle, Perrigo; Advisory boards-ByHeart, Danone Institutes International, Danone North American, General Mills, Jovie, National Dairy Council, Pepsico. SR: Other-Employment with Prolacta Bioscience, ownership of Rev. Bioscience. (Copyright © 2024 Fleming, Reyes, Donovan, Hernell, Jiang, Lönnerdal, Neu, Steinman, Sørensen, West, Kleinman and Wallingford.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu